Cargando…

The effects of denosumab and alendronate on glucocorticoid-induced osteoporosis in patients with glomerular disease: A randomized, controlled trial

INTRODUCTION: The clinical utility of denosumab for the treatment of glucocorticoid-induced osteoporosis (GIOP) has yet to be established. This study aimed to compare the effects of denosumab on bone mineral density (BMD) and bone turnover markers to those of alendronate in patients with GIOP. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales:	Iseri, Ken, Iyoda, Masayuki, Watanabe, Makoto, Matsumoto, Kei, Sanada, Daisuke, Inoue, Takashi, Tachibana, Shohei, Shibata, Takanori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5854344/ https://www.ncbi.nlm.nih.gov/pubmed/29543887 http://dx.doi.org/10.1371/journal.pone.0193846

Ejemplares similares

Anti-Phospholipase A2 Receptor (PLA2R) Antibody and Glomerular PLA2R Expression in Japanese Patients with Membranous Nephropathy
por: Hihara, Kei, et al.
Publicado: (2016)

Serum uromodulin is associated with the severity of clinicopathological findings in ANCA-associated glomerulonephritis
por: Tachibana, Shohei, et al.
Publicado: (2019)

Clinical significance of serum and mesangial galactose-deficient IgA1 in patients with IgA nephropathy
por: Wada, Yukihiro, et al.
Publicado: (2018)

Effects of denosumab versus teriparatide in glucocorticoid-induced osteoporosis patients with prior bisphosphonate treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2020)

A cross-sectional analysis of clinicopathologic similarities and differences between Henoch-Schönlein purpura nephritis and IgA nephropathy
por: Sugiyama, Motonori, et al.
Publicado: (2020)

Epidermal Growth Factor Receptor Inhibition with Erlotinib Partially Prevents Cisplatin-Induced Nephrotoxicity in Rats
por: Wada, Yukihiro, et al.
Publicado: (2014)

Persistence of Denosumab Therapy among Patients with Osteoporosis
por: Kobayashi, Kazuyoshi, et al.
Publicado: (2020)

Alendronate prevents glucocorticoid-induced osteoporosis in patients with rheumatic diseases: A meta-analysis
por: Kan, Shun-Li, et al.
Publicado: (2016)

Bone Mineral Density After Transitioning From Denosumab to Alendronate
por: Kendler, David, et al.
Publicado: (2019)

Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
por: Yanbeiy, Zeina A, et al.
Publicado: (2019)

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment
por: Hirooka, Yasuaki, et al.
Publicado: (2021)

Alendronate Sodium in the Management of Osteoporosis
por: Prinsloo, P J J, et al.
Publicado: (2006)

Effects of alendronate for treatment of glucocorticoid-induced osteoporosis: A meta-analysis of randomized controlled trials
por: Wang, Ya-Kang, et al.
Publicado: (2018)

Denosumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2017)

Comparison of the Effects of Denosumab and Alendronate on Cardiovascular and Renal Outcomes in Osteoporotic Patients
por: Hsu, Tsuen-Wei, et al.
Publicado: (2019)

Promotion effect of extracts from plastrum testudinis on alendronate against glucocorticoid-induced osteoporosis in rat spine
por: Ren, Hui, et al.
Publicado: (2017)

Therapeutic Effects of Human Mesenchymal Stem Cells in Wistar-Kyoto Rats with Anti-Glomerular Basement Membrane Glomerulonephritis
por: Suzuki, Taihei, et al.
Publicado: (2013)

Denosumab versus romosozumab for postmenopausal osteoporosis treatment
por: Kobayakawa, Tomonori, et al.
Publicado: (2021)

Seven years’ experience with alendronate in postmenopausal Japanese women with osteoporosis
por: Iwamoto, Jun, et al.
Publicado: (2010)

An effect comparison of alendronate and teriparatide in patients with glucocorticoid-induced osteoporosis: A protocol for systematic review and meta-analysis
por: Liang, Na, et al.
Publicado: (2022)

The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta-analysis
por: Yamaguchi, Yuta, et al.
Publicado: (2020)

Comparison of denosumab and oral bisphosphonates for the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
por: Jiang, Lianghai, et al.
Publicado: (2022)

Reno-protective effect of IL-34 inhibition on cisplatin-induced nephrotoxicity in mice
por: Wada, Yukihiro, et al.
Publicado: (2021)

Alendronate improves QOL of postmenopausal women with osteoporosis
por: Kawate, Hisaya, et al.
Publicado: (2010)

Denosumab for dialysis patients with osteoporosis: A cohort study
por: Kunizawa, Kyohei, et al.
Publicado: (2020)

Osteoporosis in men: epidemiology and treatment with denosumab
por: Sidlauskas, Kristel M, et al.
Publicado: (2014)

A review of denosumab for the treatment of osteoporosis
por: Miyazaki, Tsuyoshi, et al.
Publicado: (2014)

Effects of denosumab treatment in chronic liver disease patients with osteoporosis
por: Saeki, Chisato, et al.
Publicado: (2020)

Denosumab improves bone mineral density and microarchitecture and reduces bone pain in women with osteoporosis with and without glucocorticoid treatment
por: Petranova, Tzvetanka, et al.
Publicado: (2014)

Comparison of Risk of Osteoporotic Fracture in Denosumab vs Alendronate Treatment Within 3 Years of Initiation
por: Pedersen, Alma B., et al.
Publicado: (2019)

Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan
por: Mori, Takahiro, et al.
Publicado: (2021)

Hip fracture protection by alendronate treatment in postmenopausal women with osteoporosis: a review of the literature
por: Iwamoto, Jun, et al.
Publicado: (2008)

Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis
por: Yuan, Chuanjian, et al.
Publicado: (2023)

Emerging treatments for postmenopausal osteoporosis – focus on denosumab
por: Geusens, Piet
Publicado: (2009)

Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2011)

Denosumab: an investigational drug for the management of postmenopausal osteoporosis
por: Lewiecki, E Michael
Publicado: (2008)

Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
por: Min, Yong-Ki
Publicado: (2015)

Alopecia areata after denosumab treatment for osteoporosis
por: Lyakhovitsky, Anna, et al.
Publicado: (2016)

Osteoporosis Therapy With Denosumab in Organ Transplant Recipients
por: Brunova, Jana, et al.
Publicado: (2018)

Should denosumab treatment for osteoporosis be continued indefinitely?
por: Noble, Jane A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n6rj73un71s4qcdl8d2hsg7p7g